BAYER AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.41 EUR | +1.91% |
|
+4.12% | -18.50% |
| Apr. 25 | Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15 | DP |
| Apr. 25 | Human rights activists complain to OECD about Bayer over glyphosate | DP |
| Sales 2024 * | 47.18B 50.63B | Sales 2025 * | 48.08B 51.6B | Capitalization | 26.42B 28.36B |
|---|---|---|---|---|---|
| Net income 2024 * | 2.08B 2.23B | Net income 2025 * | 3.17B 3.4B | EV / Sales 2024 * | 1.26 x |
| Net Debt 2024 * | 33.11B 35.53B | Net Debt 2025 * | 29.67B 31.84B | EV / Sales 2025 * | 1.17 x |
| P/E ratio 2024 * |
12.3
x | P/E ratio 2025 * |
8.27
x | Employees | 96,931 |
| Yield 2024 * |
0.41% | Yield 2025 * |
0.86% | Free-Float | 99.97% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bayer AG
More press releases
| 1 day | +0.63% | ||
| 1 week | +2.50% | ||
| Current month | -5.40% | ||
| 1 month | +0.20% | ||
| 3 months | -17.56% | ||
| 6 months | -34.46% | ||
| Current year | -20.03% |
1 week
26.72
27.70
1 month
25.6128.94
Current year
24.9636.09
1 year
24.9660.31
3 years
24.9667.99
5 years
24.9678.34
10 years
24.96146.45
| Managers | Title | Age | Since |
|---|---|---|---|
William Anderson
CEO | Chief Executive Officer | 57 | 23-03-31 |
| Director of Finance/CFO | 54 | 18-04-25 | |
Bijoy Sagar
CTO | Chief Tech/Sci/R&D Officer | 55 | 20-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Colleen Goggins
BRD | Director/Board Member | 68 | 17-03-31 |
| Director/Board Member | 68 | 17-03-31 | |
Alberto Weisser
BRD | Director/Board Member | 67 | 21-03-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.77% | 70 M€ | -.--% | - | |
| 5.71% | 2 M€ | +13.56% | - | |
| 4.28% | 962 M€ | -.--% | - | |
| 4.10% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 27.38 | +1.78% | 297 124 |
| 24-04-25 | 26.9 | -0.28% | 3,533,816 |
| 24-04-24 | 26.97 | -1.37% | 2,710,724 |
| 24-04-23 | 27.34 | +0.11% | 3,055,329 |
| 24-04-22 | 27.32 | +3.76% | 4,999,901 |
Delayed Quote Xetra, April 25, 2024 at 11:35 am EDT
More quotes
Bayer AG is one of the world's leaders in designing, producing, and marketing pharmaceutical products and agrochemicals. Net sales are distributed by product family as follows:
- agrochemicals (48.8%): herbicides, fungicides, insecticides, etc.;
- pharmaceutical products (38%): intended for the prevention and treatment of cardiovascular and respiratory diseases, diabetes, nervous system disorders, etc.;
- OTC products and nutritional supplements (12.7%);
- other (0.5%).
Net sales are distributed geographically as follows: Germany (5.1%), Switzerland (1.2%), Europe-Middle East-Africa (23.2%), the United States (30.6%), North America (3.5%), China (7.6%), Asia-Pacific (10%), Brazil (10.4%) and Latin America (8.4%).
Sector
Pharmaceuticals
Calendar
04:00am
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
26.9
EUR
Average target price
37.05
EUR
Spread / Average Target
+37.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.03% | 28.3B | |
| +24.17% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +13.45% | 233B | |
| +6.04% | 201B | |
| -10.51% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- BAYN Stock
